Description: InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, it works on IND-enabling pharmacology and preclinical toxicology studies. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Home Page: www.inmedpharma.com
INM Technical Analysis
815 West Hastings Street
Vancouver,
BC
V6C 1B4
Canada
Phone:
604 669 7207
Officers
| Name | Title |
|---|---|
| Mr. Eric A. Adams B.S. Chem., M.I.B. | Pres, CEO & Director |
| Ms. Alexandra Diane-Janet Mancini M.Sc. | Sr. VP of Clinical & Regulatory Affairs |
| Dr. Eric Chih-Hsien Hsu | Sr. VP of Preclinical R&D |
| Dr. Sazzad Hossain M.Sc., Ph.D. | Co-Founder |
| Ms. Sarah Li CPA, CGA | VP of Accounting & Controller |
| Mr. Michael Woudenberg P.Eng. | Chief Operating Officer |
| Colin Clancy | Sr. Director of Investor Relations |
| Mr. Jerry P. Griffin | VP of Sales & Marketing |
| Dr. Shane A. Johnson Ph.D. | Sr. VP & GM of BayMedica |
| Dr. Ado Muhammad | Sr. Consultant of Medical Affairs |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.1975 |
| Price-to-Sales TTM: | 1.4334 |
| IPO Date: | 2020-11-12 |
| Fiscal Year End: | June |
| Full Time Employees: | 13 |